

## Investor Webinar Presentation

Investors are invited to participate in the Genetic Signatures Limited (ASX: GSS) investor webinar with CEO Dr John Melki covering:

- Product description and pipeline update
- Q1 financial results
- Upcoming milestones
- Question & answer session

**11am AEDT Monday 25 October 2021**

To register: [https://zoom.us/webinar/register/WN\\_bdlzN1YMQzGrhbwPjrwJw](https://zoom.us/webinar/register/WN_bdlzN1YMQzGrhbwPjrwJw)

Questions may be pre-submitted during registration or tabled during the webinar. A recorded copy of the webinar will be on the Company website after the presentation.

For further information, see our website ([www.geneticsignatures.com](http://www.geneticsignatures.com)) or contact us as below:

**Dr John Melki**

**Chief Executive Officer**

[john.melki@geneticsignatures.com](mailto:john.melki@geneticsignatures.com)

T: +61 (0)2 9870 7580

**Peter Manley**

**Chief Financial Officer**

[peter.manley@geneticsignatures.com](mailto:peter.manley@geneticsignatures.com)

**About Genetic Signatures Limited:** Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base**<sup>™</sup>. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen*<sup>™</sup> brand. Genetic Signatures' proprietary MDx **3base**<sup>™</sup> platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.